BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 18977531)

  • 1. Development of acute myeloid leukemia associated with Ph-negative clone with inv(3)(q21q26) during imatinib therapy for chronic myeloid leukemia.
    Dvorak P; Hruba M; Subrt I
    Leuk Res; 2009 Jun; 33(6):860-1. PubMed ID: 18977531
    [No Abstract]   [Full Text] [Related]  

  • 2. Acute myeloid leukemia developing during imatinib mesylate therapy for chronic myeloid leukemia in the absence of new cytogenetic abnormalities.
    Pawarode A; Sait SN; Nganga A; Coignet LJ; Barcos M; Baer MR
    Leuk Res; 2007 Nov; 31(11):1589-92. PubMed ID: 17391756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An inv(16) in Ph-negative cells of a chronic myelogenous leukemia patient after imatinib treatment.
    Rowe LR; Brothman AR; Nibley WE; Gaffney MR; Chen Z
    Cancer Genet Cytogenet; 2007 Apr; 174(1):54-6. PubMed ID: 17350467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperleukocytotic secondary acute myeloid leukemia (AML) with sole monosomy 7 as sequela of Philadelphia-chromosome positive chronic myeloid leukemia (CML).
    Hackanson B; Rückert A; Lübbert M
    Eur J Haematol; 2009 Dec; 83(6):611-2. PubMed ID: 19682063
    [No Abstract]   [Full Text] [Related]  

  • 5. Development of acute myeloid leukemia with NPM1 mutation, in Ph-negative clone, during treatment of CML with imatinib.
    Georgiou G; Efthymiou A; Vardounioti I; Boutsikas G; Angelopoulou MK; Vassilakopoulos TP; Kyrtsonis MC; Plata E; Tofas P; Bitsani A; Bartzi V; Pessach I; Dimou M; Panayiotidis P
    Leukemia; 2012 Apr; 26(4):824-6. PubMed ID: 21986839
    [No Abstract]   [Full Text] [Related]  

  • 6. Development of AML with t(8;21)(q22;q22) and RUNX1-RUNX1T1 fusion following Philadelphia-negative clonal evolution during treatment of CML with Imatinib.
    Schafhausen P; Dierlamm J; Bokemeyer C; Bruemmendorf TH; Bacher U; Zander AR; Schnittger S; Hochhaus A
    Cancer Genet Cytogenet; 2009 Feb; 189(1):63-7. PubMed ID: 19167615
    [No Abstract]   [Full Text] [Related]  

  • 7. [Emergence and decrement of Ph-negative clone with trisomy 8 in CML during imatinib therapy].
    Kimura F; Kobayashi S; Ogura K; Kobayashi A; Torikai H; Ikeda T; Sato K; Motoyoshi K
    Rinsho Ketsueki; 2004 Sep; 45(9):1058-60. PubMed ID: 15510836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful interim therapy with imatinib prior to allogeneic stem cell transplantation in Philadelphia chromosome-positive acute myeloid leukemia.
    Cho BS; Kim HJ; Lee S; Eom KS; Min WS; Lee JW; Kim CC
    Eur J Haematol; 2007 Aug; 79(2):170-3. PubMed ID: 17608710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monosomy 7 with severe myelodysplasia developing during imatinib treatment of Philadelphia-positive chronic myeloid leukemia: two cases with a different outcome.
    Navarro JT; Feliu E; Grau J; Espinet B; Colomer D; Ribera JM; Oriol A; Granada I; Juncà J; Millá F
    Am J Hematol; 2007 Sep; 82(9):849-51. PubMed ID: 17563075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clonal cytogenetic abnormalities in patients with chronic myeloid leukemia in complete cytogenetic response to imatinib mesylate.
    Espinet B; Oliveira AC; Boqué C; Domingo A; Alonso E; Solé F
    Haematologica; 2005 Apr; 90(4):556-8. PubMed ID: 15820956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Double Philadelphia-chromosome: a resistance factor on the imatinib mesylate therapy for chronic myeloid leukemia.
    Otero L; Ornellas MH; Dobbin J; de Souza Fernandez T
    Int J Lab Hematol; 2008 Aug; 30(4):346-8. PubMed ID: 18665834
    [No Abstract]   [Full Text] [Related]  

  • 12. Philadelphia-negative clonal hematopoiesis following imatinib therapy in patients with chronic myeloid leukemia: a report of nine cases and analysis of predictive factors.
    Lin Y; Bruyère H; Horsman DE; Pantzar T; Barnett MJ; Hogge DE; Nevill TJ; Nantel SH; Sutherland HJ; Toze CL; Shepherd JD; Lavoie JC; Song KW; Smith CA; Forrest DL
    Cancer Genet Cytogenet; 2006 Oct; 170(1):16-23. PubMed ID: 16965950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imatinib resistant chronic myelogenous leukemia, BCR-ABL positive by chromosome and FISH analyses but negative by PCR, in a child progressing to acute basophilic leukemia: cytogenetic follow-up.
    Moser AM; Manor E; Narkis G; Kapelushnik J
    Cancer Genet Cytogenet; 2006 Oct; 170(1):54-7. PubMed ID: 16965955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular response to imatinib in patient with Ph negative p190 BCR-ABL transcript positive chronic myeloid leukemia with cyclic leukocytosis.
    Radojkovic M; Ristic S; Pavlovic S; Colovic M
    Leuk Res; 2009 Jun; 33(6):e10-2. PubMed ID: 19091403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trisomy 6 in a CML patient receiving imatinib mesylate therapy.
    Zámecníkova A; Al Bahar S; Ramesh P
    Leuk Res; 2008 Sep; 32(9):1454-7. PubMed ID: 18294688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trisomy 8 finding treatment of imatinib mesylate in chronic myeloid leukemia cases.
    Tunca Y; Güran S
    Exp Hematol; 2005 Feb; 33(2):151. PubMed ID: 15676207
    [No Abstract]   [Full Text] [Related]  

  • 17. Reciprocal relationship between a Ph-negative clone with trisomy 8 associated with severe myelodysplasia and a Ph-positive clone following imatinib treatment in a patient with accelerated-phase chronic myelogenous leukemia (CML).
    Patchenko P; Klepfish A; Trakhtenbrot L; Rothman R; Rachmilewitz EA
    Am J Hematol; 2004 Dec; 77(4):420. PubMed ID: 15558793
    [No Abstract]   [Full Text] [Related]  

  • 18. Duplication of the Ph-chromosome as a possible mechanism of resistance to imatinib mesylate in patients with chronic myelogenous leukemia.
    Ossard-Receveur A; Bernheim A; Clausse B; Danglot G; Fauvet D; Leon B; Lozach F; Bories D; Brouzes C; Bourhis JH; Turhan AG
    Cancer Genet Cytogenet; 2005 Dec; 163(2):189-90. PubMed ID: 16337868
    [No Abstract]   [Full Text] [Related]  

  • 19. Are there new clinical parameters useful to predict response in chronic myeloid leukemia in the imatinib era?
    Breccia M; Alimena G
    Leuk Res; 2009 Nov; 33(11):1450-1. PubMed ID: 19615745
    [No Abstract]   [Full Text] [Related]  

  • 20. Gene expression analysis fails to identify patients with chronic myeloid leukemia who will achieve cytogenetic response to imatinib.
    Gambacorti-Passerini C
    Haematologica; 2005 Apr; 90(4):434. PubMed ID: 15820927
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 20.